Find Clinical Trial
Study of Combination Therapy of Gliclazide MR and Basal Insulin Versus Insulin Monotherapy to Treat Type 2 Diabetes
← Back
| Study Phase |
Phase 4 |
| Therapeutic Area |
Metabolism |
| Indication | Diabetes - Type II |
| Sponsor | Servier (Tianjin) Pharmaceutical Co. LTD. |
| Active substance/ Medical device |
GLICLAZIDE, |
| Active Substance Code | S005702 |
| Protocol Code | IC4-5702-205-CHN |
| NCT Code | NCT00736515 |
Documents and links
| Scientific publication | READ MORE  |
Servier Glossary of Terms
To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.
© 2022 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
All Rights Reserved. Servier does not sell its products over the Internet.
Accessibility
